. Author manuscript; available in PMC: 2019 Jul 25.

Published in final edited form as: Nat Rev Gastroenterol Hepatol. 2014 Apr 1;11(7):402–409. doi: 10.1038/nrgastro.2014.30

Table 2 |.

Data on efficacy of oral antiviral therapy before and during pregnancy to reduce the HBV MTCT rate

Study	Number of patients	Drug (time of treatment initiation)	Control arm	HBeAg- positive	HBV DNA level	MTCT rate (%)
Yi et al. (2013)⁴⁷	155	Lamivudine (second or third trimester)	No^*	Yes	>6 log₁₀ copies per ml	0
Xu et al. (2009)⁴⁶	89	Lamivudine (32 weeks)	Yes	Yes	>1,000 MEq/ml^‡	18
Greenup et al. (2013)⁵⁵	60	TDF (32 weeks)	No^§	ND	>7 log₁₀ IU/ml	0
Pan et al. (2013)⁵⁴	48	TDF (first trimester)	No	Yes (87.5%)	All had active chronic HBV, viral threshold for treatment not reported	0
Pan et al. (2012)⁵³	11	TDF (29 weeks)	No	Yes	≥7 log₁₀ IU/ml	0
Han et al. (2011)⁴⁸	135	Telbivudine (20–32 weeks)	Yes	Yes	>7 log₁₀ copies per ml	0
Pan et al. (2012)⁵⁰	53	Telbivudine (second or third trimester)	Yes	Yes	>6 log₁₀ copies per ml	0
Liu et al. (2013)⁵¹	86	Telbivudine (antepartum or first trimester)	No	Yes (86.0%)	>1 × 10⁵ copies per ml	0

Compared with historical cases.

^‡

1 MEq ≅ 106 copies per ml.

^§

Compared with historical cases treated with lamivudine and untreated. Abbreviations: MTCT, mother-to-child transmission; ND, not determined; TDF, tenofovir disoproxil fumarate.